|
NZ581779A
(en)
|
2005-05-17 |
2011-09-30 |
Univ Connecticut |
Composition and methods for immunomodulation in an organism comprising interleukin-15 polypeptide and interleukin-15 receptor subunit A polypeptide complex
|
|
EA016217B1
(ru)
|
2005-12-02 |
2012-03-30 |
Маунт Синай Скул Оф Медсин |
Химерные вирусы, представляющие неприродные поверхностные белки, и их применение
|
|
US9303080B2
(en)
|
2006-01-13 |
2016-04-05 |
The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, National Institutes Of Health |
Codon optimized IL-15 and IL-15R-alpha genes for expression in mammalian cells
|
|
CN101743249B
(zh)
|
2007-05-11 |
2017-08-08 |
阿尔托生物科学有限公司 |
融合分子与il‑15变异体
|
|
NZ616254A
(en)
|
2007-06-27 |
2015-04-24 |
Us Sec Dep Of Health And Human Services |
Complexes of il-15 and il-15ralpha and uses thereof
|
|
WO2018112219A1
(en)
*
|
2016-12-14 |
2018-06-21 |
Nant Holdings Ip, Llc |
Superkine
|
|
US11053299B2
(en)
|
2010-09-21 |
2021-07-06 |
Immunity Bio, Inc. |
Superkine
|
|
ES2651170T3
(es)
|
2010-09-21 |
2018-01-24 |
Altor Bioscience Corporation |
Moléculas de fusión solubles multímeras de IL-15 y métodos para elaborar y usar las mismas
|
|
PT2663579T
(pt)
|
2011-01-14 |
2017-07-28 |
Univ California |
Terapêutica de anticorpos contra a proteína r0r-1 e métodos para sua utilização
|
|
HUE037849T2
(hu)
*
|
2012-06-08 |
2018-09-28 |
Alkermes Pharma Ireland Ltd |
Cirkuláris permutációval módosított ligandumok agonistaként és antagonistaként
|
|
CA2888896A1
(en)
|
2012-10-24 |
2014-05-01 |
Admune Therapeutics Llc |
Il-15r alpha forms, cells expressing il-15r alpha forms, and therapeutic uses of il-15r alpha and il-15/il-15r alpha complexes
|
|
EP3640375A3
(en)
|
2012-12-11 |
2020-07-29 |
Albert Einstein College of Medicine |
Methods for high throughput receptor/ligand identification
|
|
CA2905272A1
(en)
|
2013-03-14 |
2014-10-02 |
Icahn School Of Medicine At Mount Sinai |
Newcastle disease viruses and uses thereof
|
|
ES2906615T3
(es)
|
2013-04-19 |
2022-04-19 |
Cytune Pharma |
Tratamiento derivado de citocinas con síndrome de fuga vascular reducido
|
|
US9629877B2
(en)
|
2013-05-14 |
2017-04-25 |
Board Of Regents, The University Of Texas System |
Human application of engineered chimeric antigen receptor (CAR) T-cells
|
|
MX374291B
(es)
|
2013-08-08 |
2025-03-06 |
Cytune Pharma |
Modulocinas basadas en dominio sushi de interleucina-15 (il-15) y receptor alfa de interleucina-15 (il-15ra).
|
|
HUE046964T2
(hu)
*
|
2013-08-08 |
2020-04-28 |
Cytune Pharma |
Kombinált gyógyászati készítmény
|
|
JP7097667B2
(ja)
|
2013-09-27 |
2022-07-08 |
マサチューセッツ インスティテュート オブ テクノロジー |
無担体生物活性タンパク質ナノ構造体
|
|
US10206980B2
(en)
*
|
2014-01-08 |
2019-02-19 |
Shanghai Hengrui Pharmaceutical Co., Ltd. |
IL-15 heterodimeric protein and uses thereof
|
|
WO2015109124A2
(en)
*
|
2014-01-15 |
2015-07-23 |
Kadmon Corporation, Llc |
Immunomodulatory agents
|
|
RU2021123419A
(ru)
|
2014-02-14 |
2021-10-22 |
Борд Оф Риджентс, Дзе Юниверсити Оф Техас Систем |
Химерные антигенные рецепторы и способы их получения
|
|
EP3110443A4
(en)
|
2014-02-27 |
2017-11-15 |
Viralytics Limited |
Combination method for treatment of cancer
|
|
EP2915569A1
(en)
|
2014-03-03 |
2015-09-09 |
Cytune Pharma |
IL-15/IL-15Ralpha based conjugates purification method
|
|
US10464982B2
(en)
|
2014-04-23 |
2019-11-05 |
Emory University |
Compositions of GM-CSF and interleukin fusions for immune modulation and uses related thereto
|
|
CA2948462A1
(en)
|
2014-05-15 |
2015-11-19 |
National University Of Singapore |
Modified natural killer cells and uses thereof
|
|
CN112494646A
(zh)
*
|
2014-06-30 |
2021-03-16 |
阿尔托生物科学有限公司 |
基于il-15的分子及其方法和用途
|
|
EP3174974B1
(en)
|
2014-07-29 |
2020-05-20 |
Novartis AG |
Il-15 and il-15ralpha heterodimer dose escalation regimens for treating conditions
|
|
MA41044A
(fr)
|
2014-10-08 |
2017-08-15 |
Novartis Ag |
Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
|
|
EA201790834A1
(ru)
|
2014-10-14 |
2018-01-31 |
Новартис Аг |
Молекулы антител к pd-l1 и их применение
|
|
WO2016081601A1
(en)
|
2014-11-19 |
2016-05-26 |
Memorial Sloan-Kettering Cancer Center |
Methods and compositions for cancer treating conditions relating to over expressions of epha2
|
|
HRP20201572T1
(hr)
*
|
2014-12-19 |
2020-12-11 |
Jiangsu Hengrui Medicine Co., Ltd. |
Interleukin 15 proteinski kompleks i njegova uporaba
|
|
CN104830884A
(zh)
*
|
2015-01-22 |
2015-08-12 |
苏州大学 |
一种携带IL-15/sIL-15Ra融合基因的微环DNA表达载体的构建方法
|
|
EP3064507A1
(en)
|
2015-03-06 |
2016-09-07 |
Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts |
Fusion proteins comprising a binding protein and an interleukin-15 polypeptide having a reduced affinity for IL15ra and therapeutic uses thereof
|
|
CN112574316A
(zh)
*
|
2015-07-02 |
2021-03-30 |
博际生物医药科技(杭州)有限公司 |
用于肿瘤靶向治疗的白细胞介素-15融合蛋白
|
|
EP3316902A1
(en)
|
2015-07-29 |
2018-05-09 |
Novartis AG |
Combination therapies comprising antibody molecules to tim-3
|
|
ES2878188T3
(es)
|
2015-07-29 |
2021-11-18 |
Novartis Ag |
Terapias de combinación que comprenden moléculas de anticuerpos contra LAG-3
|
|
US20180222982A1
(en)
|
2015-07-29 |
2018-08-09 |
Novartis Ag |
Combination therapies comprising antibody molecules to pd-1
|
|
EP3334417A4
(en)
*
|
2015-08-12 |
2019-07-17 |
Massachusetts Institute of Technology |
CELL SURFACE COUPLING OF NANOPARTICLES
|
|
AU2016326575A1
(en)
*
|
2015-09-25 |
2018-04-12 |
Altor Bioscience Corporation |
Interleukin-15 superagonist significantly enhances graft-versus-tumor activity
|
|
RU2770001C2
(ru)
*
|
2015-10-06 |
2022-04-14 |
Риджентс Оф Дзе Юниверсити Оф Миннесота |
Терапевтические соединения и способы
|
|
WO2017106656A1
(en)
|
2015-12-17 |
2017-06-22 |
Novartis Ag |
Antibody molecules to pd-1 and uses thereof
|
|
WO2017143092A1
(en)
|
2016-02-19 |
2017-08-24 |
Nant Holdings Ip, Llc |
Methods of immunogenic modulation
|
|
JP2019519516A
(ja)
|
2016-05-18 |
2019-07-11 |
モデルナティーエックス， インコーポレイテッド |
がんの治療のためのｍＲＮＡ併用療法
|
|
BR112018073606A2
(pt)
|
2016-05-18 |
2019-02-26 |
Cue Biopharma, Inc. |
polipeptídeos multiméricos moduladores de células t e métodos de uso dos mesmos
|
|
WO2017201131A1
(en)
|
2016-05-18 |
2017-11-23 |
Albert Einstein College Of Medicine, Inc. |
Variant pd-l1 polypeptides, t-cell modulatory multimeric polypeptides, and methods of use thereof
|
|
JP7037506B2
(ja)
*
|
2016-05-27 |
2022-03-16 |
アルター・バイオサイエンス・コーポレーション |
Ｃｄ３結合ドメインを有する多量体ｉｌ－１５系分子の構築及び特性評価
|
|
US11472856B2
(en)
|
2016-06-13 |
2022-10-18 |
Torque Therapeutics, Inc. |
Methods and compositions for promoting immune cell function
|
|
WO2018011573A1
(en)
*
|
2016-07-12 |
2018-01-18 |
Kymab Limited |
Animals, cells, ligands, polypeptides & methods
|
|
EP3515471A4
(en)
*
|
2016-09-23 |
2020-07-01 |
The Regents of The University of California |
SELF-MODIFIED LENTIVIRAL-MODIFIED IRRADIATED WHOLE CELL ANTI-TUMOR VACCINES TO EXPRESS CD80, IL-15 AND THE IL-15 ALPHA RECEPTOR
|
|
MA46534A
(fr)
*
|
2016-10-14 |
2019-08-21 |
Xencor Inc |
Protéines de fusion fc hétérodimères il15/il15r
|
|
EP3529350A1
(en)
*
|
2016-10-19 |
2019-08-28 |
H. Hoffnabb-La Roche Ag |
Method for producing an immunoconjugate
|
|
KR20190091264A
(ko)
|
2016-10-21 |
2019-08-05 |
알토 바이오사이언스 코포레이션 |
다량체 il-15 기반 분자
|
|
WO2018119114A1
(en)
|
2016-12-22 |
2018-06-28 |
Cue Biopharma, Inc. |
T-cell modulatory multimeric polypeptides and methods of use thereof
|
|
CN108250301A
(zh)
*
|
2016-12-29 |
2018-07-06 |
天津天锐生物科技有限公司 |
一种多靶点嵌合抗原受体
|
|
CN108250302A
(zh)
*
|
2016-12-29 |
2018-07-06 |
天津天锐生物科技有限公司 |
一种多功能蛋白质
|
|
US11851471B2
(en)
|
2017-01-09 |
2023-12-26 |
Cue Biopharma, Inc. |
T-cell modulatory multimeric polypeptides and methods of use thereof
|
|
CN110177568A
(zh)
|
2017-01-20 |
2019-08-27 |
诺华股份有限公司 |
用于治疗癌症的组合疗法
|
|
US20200237874A1
(en)
|
2017-01-20 |
2020-07-30 |
Novartis Ag |
Combination therapy for the treatment of cancer
|
|
US11129883B2
(en)
*
|
2017-03-06 |
2021-09-28 |
Altor BioScience, LLC. |
IL-15-based fusions to IL-12 and IL-18
|
|
EP3596118B1
(en)
|
2017-03-15 |
2024-08-21 |
Cue Biopharma, Inc. |
Combination of multimeric fusion polypeptides and immune checkpoint inhibitor for treating hpv-associated cancer
|
|
EP3600356A4
(en)
|
2017-03-27 |
2020-12-23 |
National University of Singapore |
TRUNCATED NKG2D CHEMERIC RECEPTORS AND THEIR USES IN NATURAL KILLER CELL IMMUNOTHERAPY
|
|
KR102624509B1
(ko)
|
2017-03-27 |
2024-01-12 |
싱가포르국립대학교 |
자연 살해 세포의 ex vivo 확장 및 활성화를 위한 자극성 세포주
|
|
US20190048055A1
(en)
*
|
2017-03-31 |
2019-02-14 |
Altor Bioscience Corporation |
Alt-803 in combination with anti-cd38 antibody for cancer therapies
|
|
JOP20190256A1
(ar)
|
2017-05-12 |
2019-10-28 |
Icahn School Med Mount Sinai |
فيروسات داء نيوكاسل واستخداماتها
|
|
WO2018229706A1
(en)
|
2017-06-16 |
2018-12-20 |
Novartis Ag |
Combination therapy for the treatment of cancer
|
|
JP2020524167A
(ja)
|
2017-06-20 |
2020-08-13 |
ナントクエスト インコーポレイテッド |
Ｎｋ−９２細胞とｉｌ−１５アゴニストの併用療法
|
|
US12275787B2
(en)
|
2017-06-21 |
2025-04-15 |
Icell Gene Therapeutics Llc |
Chimeric antigen receptors (CARs), compositions and methods thereof
|
|
WO2019006472A1
(en)
|
2017-06-30 |
2019-01-03 |
Xencor, Inc. |
TARGETED HETETRODIMERIC FUSION PROTEINS CONTAINING IL-15 / IL-15RA AND ANTIGEN-BINDING DOMAINS
|
|
AU2018298060B2
(en)
|
2017-07-03 |
2021-02-25 |
Torque Therapeutics, Inc. |
Immunostimulatory fusion molecules and uses thereof
|
|
RU2749342C1
(ru)
|
2017-07-25 |
2021-06-08 |
Цзянсу Хэнжуй Медицин Ко., Лтд. |
Фармацевтическая композиция на основе белкового комплекса il-15 и ее применения
|
|
KR20200090742A
(ko)
|
2017-08-28 |
2020-07-29 |
알토 바이오사이언스 엘엘씨 |
Il-7 및 il-21에의 il-15 기반 융합
|
|
KR20210032924A
(ko)
|
2017-09-05 |
2021-03-25 |
토크 테라퓨틱스, 인코포레이티드 |
치료용 단백질 조성물 및 그의 제조 및 사용 방법
|
|
EP3694886A4
(en)
|
2017-10-12 |
2021-09-22 |
iCell Gene Therapeutics, LLC |
COMPOSITE CHIMERIC ANTIGEN RECEPTOR (CCAR) TARGETING MULTIPLE ANTIGENS, COMPOSITIONS AND METHOD OF USING THEREOF
|
|
CN109705211B
(zh)
|
2017-10-26 |
2020-08-18 |
苏州复融生物技术有限公司 |
一种IgG1 Fc单体及其应用
|
|
WO2019108065A1
(en)
|
2017-12-01 |
2019-06-06 |
Merus N.V. |
Use of bispecific antibody and il-15 for combination therapy
|
|
JP7386161B2
(ja)
|
2017-12-19 |
2023-11-24 |
ブレイズ バイオサイエンス， インコーポレイテッド |
腫瘍ホーミング及び細胞透過性ペプチド免疫抗がん剤複合体、ならびにそれらの使用方法
|
|
US11413050B2
(en)
|
2018-01-05 |
2022-08-16 |
Theragi, LLC |
Surgical clip and deployment system
|
|
EP3737689A4
(en)
|
2018-01-09 |
2021-12-01 |
Cue Biopharma, Inc. |
MULTIMERIC T CELL-MODULATING POLYPEPTIDES AND METHOD OF USING THEREOF
|
|
CN111936156A
(zh)
|
2018-02-02 |
2020-11-13 |
诺华股份有限公司 |
用于治疗癌症的STING激动剂和IL-15/IL15-Ra的组合
|
|
JP7360174B2
(ja)
|
2018-02-09 |
2023-10-12 |
ナショナル ユニヴァーシティー オブ シンガポール |
ナチュラルキラー細胞免疫療法における活性化キメラ受容体及びその使用
|
|
BR112020017016A2
(pt)
*
|
2018-02-26 |
2020-12-29 |
Synthorx, Inc. |
Conjugados da il-15 e usos dos mesmos
|
|
EP3759129A1
(en)
|
2018-02-28 |
2021-01-06 |
Pfizer Inc |
Il-15 variants and uses thereof
|
|
EP3773657A4
(en)
*
|
2018-03-26 |
2021-12-08 |
Altor Bioscience LLC |
ANTI-PDL1, IL-15 AND TGF BETA RECEPTOR COMBINATION MOLECULES
|
|
JP7334985B2
(ja)
|
2018-04-02 |
2023-08-29 |
ナショナル ユニヴァーシティー オブ シンガポール |
免疫細胞で発現される膜結合抗サイトカイン非シグナル伝達バインダーによるヒトサイトカインの中和
|
|
WO2019195420A1
(en)
*
|
2018-04-04 |
2019-10-10 |
Nant Holding IP, LLC |
Advanced avartar dendritic cells
|
|
KR20210010862A
(ko)
|
2018-04-18 |
2021-01-28 |
젠코어 인코포레이티드 |
IL-15/IL-15Rα Fc-융합 단백질 및 PD-1 항원 결합 도메인을 함유하는 PD-1 표적화 이종이량체 융합 단백질 및 이의 용도
|
|
EP3781598A1
(en)
|
2018-04-18 |
2021-02-24 |
Xencor, Inc. |
Tim-3 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and tim-3 antigen binding domains
|
|
MA52289A
(fr)
|
2018-04-18 |
2021-02-24 |
Xencor Inc |
Protéines de fusion fc hétérodimères il-15/il-15ra et leurs utilisations
|
|
WO2019204646A1
(en)
*
|
2018-04-18 |
2019-10-24 |
Xencor, Inc. |
Lag-3 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and lag-3 antigen binding domains
|
|
CN111988991B
(zh)
*
|
2018-04-26 |
2023-09-15 |
豪夫迈·罗氏有限公司 |
用于追踪动物种群中的动物的方法和系统
|
|
CN110437339B
(zh)
|
2018-05-04 |
2021-08-13 |
免疫靶向有限公司 |
一种以白介素15为活性成分的融合蛋白型药物前体
|
|
EP3806888B1
(en)
|
2018-06-12 |
2024-01-31 |
Obsidian Therapeutics, Inc. |
Pde5 derived regulatory constructs and methods of use in immunotherapy
|
|
AU2019288471B2
(en)
*
|
2018-06-22 |
2024-11-21 |
Cugene Inc. |
Novel interleukin-15 (1L-15) fusion proteins and uses thereof
|
|
EP3810624A4
(en)
|
2018-06-22 |
2022-07-06 |
Cugene Inc. |
Cytokine-based bioactivatable drugs and methods of uses thereof
|
|
WO2019246563A1
(en)
|
2018-06-22 |
2019-12-26 |
Kite Pharma, Inc. |
Chimeric transmembrane proteins and uses thereof
|
|
WO2020023713A1
(en)
*
|
2018-07-26 |
2020-01-30 |
Nantbio, Inc. |
Tri-cytokine txm compositions and methods
|
|
US11795203B2
(en)
|
2018-07-30 |
2023-10-24 |
Jinyu Zhang |
Protein heterodimer and use thereof
|
|
US12350316B2
(en)
|
2018-08-16 |
2025-07-08 |
Nantbio, Inc. |
IL7-IL 15 TxM compositions and methods
|
|
WO2020037215A1
(en)
|
2018-08-17 |
2020-02-20 |
Icahn School Of Medicine At Mount Sinai |
Recombinant newcastle disease viruses and uses thereof for the prevention of rsv disease or human metapneumovirus disease
|
|
CN112601758A
(zh)
|
2018-08-29 |
2021-04-02 |
新加坡国立大学 |
特异性刺激经基因修饰免疫细胞的存活和扩增的方法
|
|
CN112888445B
(zh)
*
|
2018-08-30 |
2025-06-10 |
免疫生物公司 |
治疗老年化相关病症的方法
|
|
JP7407822B2
(ja)
|
2018-08-30 |
2024-01-04 |
エイチシーダブリュー バイオロジックス インコーポレイテッド |
単鎖キメラポリペプチドおよびその使用
|
|
EP4659757A2
(en)
|
2018-08-30 |
2025-12-10 |
ImmunityBio, Inc. |
Multi-chain chimeric polypeptides and uses thereof
|
|
CN113286812B
(zh)
|
2018-09-27 |
2025-05-30 |
西里欧发展公司 |
掩蔽型细胞因子多肽
|
|
US11701408B2
(en)
|
2018-10-11 |
2023-07-18 |
Nantcell, Inc. |
Treatment of immunosuppressed subjects
|
|
CR20210239A
(es)
|
2018-10-12 |
2021-12-15 |
Xencor Inc |
Proteínas de fusión de il-15/il-15ralfa-fc dirigidas a pd-1 y usos de las mismas en terapias combinadas
|
|
IL282193B2
(en)
|
2018-10-19 |
2024-10-01 |
Univ Minnesota |
Nk engager molecules and methods of use thereof
|
|
EP3896089A4
(en)
|
2018-12-13 |
2022-09-07 |
Jiangsu Hengrui Medicine Co., Ltd. |
USE OF IL-15 PROTEIN COMPLEXES IN CONJUNCTION WITH PD-L1 ANTIBODIES FOR THE TREATMENT OF TUMOR DISEASES
|
|
WO2020132646A1
(en)
|
2018-12-20 |
2020-06-25 |
Xencor, Inc. |
Targeted heterodimeric fc fusion proteins containing il-15/il-15ra and nkg2d antigen binding domains
|
|
EP3898685A1
(en)
|
2018-12-20 |
2021-10-27 |
Merus N.V. |
Clec12axcd3 bispecific antibodies and methods for the treatment of disease
|
|
EP3908314A4
(en)
*
|
2019-01-11 |
2023-05-10 |
Memorial Sloan Kettering Cancer Center |
MULTIMERIZATION OF IL-15/IL-15R ALPHA-FC COMPLEXES TO IMPROVE IMMUNOTHERAPY
|
|
US12325734B2
(en)
|
2019-01-15 |
2025-06-10 |
Altor Bioscience Llc |
Human immunodeficiency virus-specific T cell receptors
|
|
CN118546959A
(zh)
|
2019-03-05 |
2024-08-27 |
恩卡尔塔公司 |
Cd19定向性嵌合抗原受体及其在免疫疗法中的用途
|
|
US20220218789A1
(en)
|
2019-05-10 |
2022-07-14 |
Nant Holdings Ip, Llc |
Nogapendekin Alfa-Inbakicept For Immune Stimulant Therapies And Treatment Of Viral Infections
|
|
US12085571B2
(en)
|
2019-06-13 |
2024-09-10 |
Immunitybio, Inc. |
Biological deposit labeling and tracking including isotope, rare earth metal or mitochondria tags
|
|
WO2020257639A1
(en)
|
2019-06-21 |
2020-12-24 |
HCW Biologics, Inc. |
Multi-chain chimeric polypeptides and uses thereof
|
|
JP7213976B2
(ja)
|
2019-07-08 |
2023-01-27 |
イミュニティーバイオ、インコーポレイテッド |
単核細胞由来のｎｋ細胞
|
|
US11453862B2
(en)
|
2019-07-08 |
2022-09-27 |
Immunitybio, Inc. |
Mononuclear cell derived NK cells
|
|
US11364291B1
(en)
|
2019-07-18 |
2022-06-21 |
Nantcell, Inc. |
Bacillus Calmette-Guerin (BCG) and antigen presenting cells for treatment of bladder cancer
|
|
CN110478474B
(zh)
*
|
2019-08-21 |
2020-06-02 |
启辰生生物科技(珠海)有限公司 |
免疫调节剂、疫苗、细胞及应用
|
|
CN114787196A
(zh)
*
|
2019-08-29 |
2022-07-22 |
南特生物科学公司 |
修饰的n-810及其方法
|
|
US20230092895A1
(en)
|
2019-08-30 |
2023-03-23 |
Obsidian Therapeutics, Inc. |
Tandem cd19 car-based compositions and methods for immunotherapy
|
|
RU2753282C2
(ru)
*
|
2019-09-19 |
2021-08-12 |
Закрытое Акционерное Общество "Биокад" |
ИММУНОЦИТОКИН, ВКЛЮЧАЮЩИЙ ГЕТЕРОДИМЕРНЫЙ БЕЛКОВЫЙ КОМПЛЕКС НА ОСНОВЕ IL-15/IL-15Rα, И ЕГО ПРИМЕНЕНИЕ
|
|
TW202128757A
(zh)
|
2019-10-11 |
2021-08-01 |
美商建南德克公司 |
具有改善之特性的 PD-1 標靶 IL-15/IL-15Rα FC 融合蛋白
|
|
CN115315434A
(zh)
*
|
2019-12-05 |
2022-11-08 |
免疫靶向有限公司 |
白细胞介素15融合蛋白和前药及其组合物和方法
|
|
CN113135996A
(zh)
*
|
2019-12-09 |
2021-07-20 |
启愈生物技术(上海)有限公司 |
一种双特异抗体及其应用
|
|
IL294257A
(en)
*
|
2019-12-31 |
2022-08-01 |
Navrogen Inc |
The composition of engineered monoclonal antibodies that are resistant to immunosuppressive cancer factors and their use
|
|
CN115210250B
(zh)
|
2020-01-08 |
2025-11-18 |
黑曜石疗法公司 |
用于可调节性调控转录的组合物和方法
|
|
WO2021142476A1
(en)
|
2020-01-12 |
2021-07-15 |
Dragonfly Therapeutics, Inc. |
Single-chain polypeptides
|
|
CA3165161A1
(en)
*
|
2020-01-31 |
2021-08-05 |
Clare KERCHER |
Ultrabright fluorescent nanocomposite structures for enhanced fluorescent bioassays
|
|
EP4100425A1
(en)
*
|
2020-02-05 |
2022-12-14 |
Novartis AG |
Cho cell expressing il-15 heterodimers
|
|
WO2021163369A2
(en)
|
2020-02-11 |
2021-08-19 |
HCW Biologics, Inc. |
Methods of treating age-related and inflammatory diseases
|
|
JP2023519107A
(ja)
|
2020-02-11 |
2023-05-10 |
エイチシーダブリュー バイオロジックス インコーポレイテッド |
制御性ｔ細胞を活性化する方法
|
|
CN115362169A
(zh)
|
2020-02-11 |
2022-11-18 |
Hcw生物科技公司 |
色谱树脂以及其用途
|
|
WO2021183717A1
(en)
|
2020-03-11 |
2021-09-16 |
Nantcell, Inc. |
Proteinaceous therapeutics
|
|
WO2021202354A1
(en)
*
|
2020-03-30 |
2021-10-07 |
Proviva Therapeutics (Hong Kong) Limited |
Il-2/il-15 compositions and methods of use thereof
|
|
TW202214290A
(zh)
|
2020-04-22 |
2022-04-16 |
瑞士商諾華公司 |
異源二聚體人介白素－１５（ｈｅｔｉｌ－１５）之藥物組成物及藥物產品
|
|
JP7734693B2
(ja)
|
2020-04-29 |
2025-09-05 |
イミュニティーバイオ インコーポレイテッド |
抗ｃｄ２６タンパク質及びそれらの使用法
|
|
AU2021272895A1
(en)
|
2020-05-12 |
2022-09-22 |
Cue Biopharma, Inc. |
Multimeric T-cell modulatory polypeptides and methods of use thereof
|
|
US11318189B1
(en)
|
2020-05-13 |
2022-05-03 |
Nantcell, Inc. |
IL-15 agonist drug combinations for immune therapy
|
|
US12024545B2
(en)
|
2020-06-01 |
2024-07-02 |
HCW Biologics, Inc. |
Methods of treating aging-related disorders
|
|
US20230226203A1
(en)
*
|
2020-06-18 |
2023-07-20 |
Proviva Therapeutics (Hong Kong) Limited |
Activatable procytokines
|
|
US12252525B2
(en)
|
2020-07-31 |
2025-03-18 |
Nantbio, Inc. |
Chimeric T cell receptors, nucleic acids, and methods of making and using the same
|
|
US20230280356A1
(en)
|
2020-08-03 |
2023-09-07 |
Nantcell, Inc. |
Drug-specific pharmacokinetic assay for il-15 superagonist
|
|
EP4211149A4
(en)
|
2020-09-09 |
2024-10-09 |
Cue Biopharma, Inc. |
MULTIMERIC POLYPEPTIDES MODULATING MHC CLASS II T CELLS FOR THE TREATMENT OF TYPE 1 DIABETES MELLITUS (T1D) AND METHODS OF USE THEREOF
|
|
WO2022057851A1
(en)
*
|
2020-09-16 |
2022-03-24 |
Beigene, Ltd. |
Interleukin 15 constructs and methods of use
|
|
WO2022115865A2
(en)
|
2020-11-25 |
2022-06-02 |
Xilio Development, Inc. |
Tumor-specific cleavable linkers
|
|
US11591381B2
(en)
|
2020-11-30 |
2023-02-28 |
Crispr Therapeutics Ag |
Gene-edited natural killer cells
|
|
EP4255922A1
(en)
|
2020-12-03 |
2023-10-11 |
Century Therapeutics, Inc. |
Genetically engineered cells and uses thereof
|
|
US11661459B2
(en)
|
2020-12-03 |
2023-05-30 |
Century Therapeutics, Inc. |
Artificial cell death polypeptide for chimeric antigen receptor and uses thereof
|
|
JP2024500847A
(ja)
|
2020-12-18 |
2024-01-10 |
センチュリー セラピューティクス，インコーポレイテッド |
適合可能な受容体特異性を有するキメラ抗原受容体システム
|
|
WO2022140665A1
(en)
*
|
2020-12-23 |
2022-06-30 |
TCR2 Therapeutics Inc. |
Compositions and methods for tcr reprogramming using fusion proteins
|
|
CN113321736B
(zh)
*
|
2020-12-30 |
2024-01-09 |
苏州复融生物技术有限公司 |
一种长效化白介素15融合蛋白及其制备方法和应用
|
|
WO2022144632A1
(en)
|
2020-12-30 |
2022-07-07 |
Crispr Therapeutics Ag |
Compositions and methods for differentiating stem cells into nk cells
|
|
EP4284919A1
(en)
|
2021-01-29 |
2023-12-06 |
Iovance Biotherapeutics, Inc. |
Methods of making modified tumor infiltrating lymphocytes and their use in adoptive cell therapy
|
|
KR20230160294A
(ko)
|
2021-03-24 |
2023-11-23 |
알케르메스, 인코포레이티드 |
Upar 항체 및 이를 갖는 융합 단백질
|
|
JP2024512714A
(ja)
*
|
2021-03-31 |
2024-03-19 |
アンウィタ バイオサイエンシス， インク． |
融合タンパク質、医薬組成物、及び治療適用
|
|
CA3217865A1
(en)
|
2021-04-28 |
2022-11-03 |
Minotaur Therapeutics, Inc. |
Humanized chimeric bovine antibodies and methods of use
|
|
CN113321740B
(zh)
*
|
2021-05-08 |
2023-07-18 |
上海交通大学 |
一种融合蛋白及其制备方法和用途
|
|
AU2022283438A1
(en)
*
|
2021-05-28 |
2024-01-18 |
Akso Biopharmaceutical, Inc. |
BISPECIFIC FC FUSION PROTEINS WITH sPD-1 AND IL-15
|
|
US12180492B2
(en)
|
2021-06-09 |
2024-12-31 |
Immunitybio, Inc. |
Methods and systems for producing a protein of interest in a plant
|
|
CN113736810B
(zh)
*
|
2021-09-08 |
2024-05-24 |
苏州因特药物研发有限公司 |
构建体、载体、蛋白、细胞、制备方法、产品及应用
|
|
US20240415964A1
(en)
|
2021-11-02 |
2024-12-19 |
Immunitybio, Inc. |
Natural killer cells for chordoma therapy
|
|
WO2023086772A1
(en)
|
2021-11-12 |
2023-05-19 |
Xencor, Inc. |
Bispecific antibodies that bind to b7h3 and nkg2d
|
|
WO2023141505A1
(en)
|
2022-01-22 |
2023-07-27 |
Nantcell, Inc. |
Fusion molecules of ctla4 and il-15
|
|
CN116854821A
(zh)
|
2022-08-15 |
2023-10-10 |
海徕科(北京)生物技术有限公司 |
IL-15突变体-Fc/IL-15Rα亚基-Fc异源二聚体及其用途
|
|
EP4335870A1
(en)
|
2022-09-06 |
2024-03-13 |
NantCell, Inc. |
Peptide therapeutics against sars-cov-2 spike protein
|
|
WO2024102636A1
(en)
|
2022-11-07 |
2024-05-16 |
Xencor, Inc. |
Bispecific antibodies that bind to b7h3 and mica/b
|
|
WO2024118836A1
(en)
|
2022-11-30 |
2024-06-06 |
Iovance Biotherapeutics, Inc. |
Processes for production of tumor infiltrating lymphocytes with shortened rep step
|
|
WO2024199355A1
(en)
*
|
2023-03-29 |
2024-10-03 |
Starna Therapeutics |
Nucleic acids encoding therapeutic polypeptides and lipid nanoparticle composition comprising the nucleic acids
|
|
WO2024253944A2
(en)
*
|
2023-06-06 |
2024-12-12 |
Jecho Laboratories, Inc. |
Interleukin-15 fusion protein and methods of use
|
|
WO2025010111A1
(en)
*
|
2023-07-05 |
2025-01-09 |
Nanotein Technologies, Inc. |
Cell signaling complexes and uses thereof
|
|
TW202509219A
(zh)
|
2023-07-13 |
2025-03-01 |
美商艾歐凡斯生物治療公司 |
編碼細胞介素之慢病毒載體及其用於製備腫瘤浸潤性淋巴球之用途
|
|
WO2025019077A1
(en)
|
2023-07-18 |
2025-01-23 |
Nanotein Technologies, Inc. |
Reagents, reagent kits, and culture media for activating and expanding immune cells and uses thereof
|
|
WO2025076124A1
(en)
*
|
2023-10-02 |
2025-04-10 |
Immunitybio, Inc. |
Methods of generating, stimulating, or increasing proliferation of different subsets of cd8+ t cells
|
|
WO2025085672A1
(en)
|
2023-10-17 |
2025-04-24 |
Xencor, Inc. |
Bispecific antibodies that bind to nkp46 and mica/b
|
|
WO2025096644A1
(en)
*
|
2023-10-31 |
2025-05-08 |
Immunitybio, Inc. |
Multi-chain chimeric polypeptides and use thereof in the treatment of advanced solid tumors
|
|
CN118108809B
(zh)
*
|
2024-03-15 |
2025-02-28 |
西湖实验室(生命科学和生物医学浙江省实验室) |
一种跨膜荧光蛋白、水溶荧光蛋白及其用途
|